loading page

Enhanced Level of Lysosomal associated membrane protein 2 isoform A Participates in CD4+ T Cell Hyperactivity in Patients with Primary Biliary Cholangitis
  • +8
  • Keshuai Sun,
  • Shuoyi Ma,
  • Siyuan Tian,
  • Miao Zhang,
  • Bo Li,
  • Xia Zhou,
  • Xiaohong Zheng,
  • Yansheng Liu,
  • Xinmin Zhou,
  • Lu Wang,
  • Ying Han
Keshuai Sun
Fourth Military Medical University

Corresponding Author:[email protected]

Author Profile
Shuoyi Ma
Fourth Military Medical University
Author Profile
Siyuan Tian
Fourth Military Medical University
Author Profile
Miao Zhang
Fourth Military Medical University
Author Profile
Bo Li
Fourth Military Medical University
Author Profile
Xia Zhou
Fourth Military Medical University
Author Profile
Xiaohong Zheng
Fourth Military Medical University
Author Profile
Yansheng Liu
Fourth Military Medical University
Author Profile
Xinmin Zhou
Fourth Military Medical University
Author Profile
Lu Wang
Fourth Military Medical University
Author Profile
Ying Han
Fourth Military Medical University
Author Profile

Abstract

Primary biliary cholangitis (PBC) is an immune-mediated chronic cholestasis. The disruption of T cell homeostasis plays an important role in PBC pathogenesis. Lysosomal associated membrane protein 2 isoform A (LAMP-2A) has been implicated in the regulation of CD4+ T cell responses, therefore we aim to evaluate the activation state of CD4+ T cells in PBC, and to investigate the role of LAMP-2A in it. The peripheral blood of PBC patients (PBC, n=42) and healthy controls (HC, n=20) were phenotypically analyzed, and LAMP-2A expression in CD4+ T cells was assessed by flow cytometry. Naïve CD4+ T cells of PBC patients were isolated and activated in vitro to estimate their activation responses. Additionally, we assessed the changes induced by silencing LAMP-2A expression. We found that CD4+ T cells of PBC patients exhibited significant hyperactivity, and naïve CD4+ T cells showed high LAMP-2A expression, which could be a novel biomarker for PBC activity. Moreover, by interfering with LAMP-2A expression in vitro, the overreactions of PBC naïve CD4+ T cells were reversed. Our study will help to clarify that increased LAMP-2A expression in the naïve CD4+ T cells of PBC patients may lead to a tendency for increased activation responses, which may be involved in the development and progression of PBC. To reverse the hyperactivity of CD4+ T cells and reduce the resulting biliary injury, LAMP-2A could be a novel therapeutic target for the treatment of PBC.
28 Jan 2020Submitted to Clinical & Experimental Immunology
28 Jan 2020Assigned to Editor
28 Jan 2020Submission Checks Completed